A review of monoamine transporter-ligand interactions

Current Computer-Aided Drug Design

Volumn 9, Issue 4, 2013, Pages 556-568

  Immadisetty, Kalyan ^a   Madura, Jeffry D ^a  

^a DUQUESNE UNIVERSITY   (United States)

Author keywords

Drug discovery; Force field; Free energy calculations; Homology model; Leucine transporter; Monoamine transporters

Indexed keywords

AMINES; AMINO ACIDS; CELL MEMBRANES; DISEASES; DRUG INTERACTIONS; FREE ENERGY; LIGANDS; NEUROPHYSIOLOGY; PROTEINS;

DOPAMINE; DRUG DISCOVERY; FORCEFIELDS; FREE-ENERGY CALCULATIONS; HOMOLOGY MODELING; LEUCINE TRANSPORTER; LIGAND INTERACTIONS; MONOAMINE TRANSPORTER; PLASMA MEMBRANE PROTEIN; SYMPORTERS;

BINDING ENERGY;

AMITRIPTYLINE; AMOXAPINE; ATOMOXETINE; BUTRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DESVENLAFAXINE; DOSULEPIN; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETIN; FLUVOXAMINE; IMIPRAMINE; LOFEPRAMINE; MILNACIPRAN; MIRTAZAPINE; NEUROTRANSMITTER; NORTRIPTYLINE; OPIPRAMOL; PAROXETINE; PROTRIPTYLINE; REBOXETINE; SERTRALINE; SIBUTRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VESICULAR MONOAMINE TRANSPORTER; VILOXAZINE;

ANXIETY; ATTENTION DEFICIT DISORDER; BINDING AFFINITY; DEPRESSION; HOMEOSTASIS; OBESITY; PARKINSON DISEASE; PROTEIN INTERACTION; QUANTUM MECHANICAL; REVIEW; SCHIZOPHRENIA; SEQUENCE HOMOLOGY; SEXUAL DYSFUNCTION; SIMULATION; SLEEP DISORDER; THERMODYNAMICS;

COMPUTER-AIDED DESIGN; DOPAMINE; DRUG DESIGN; HUMANS; LIGANDS; MEMBRANE TRANSPORT PROTEINS; MOLECULAR TARGETED THERAPY; NOREPINEPHRINE; PROTEIN BINDING; SEROTONIN; TIME FACTORS;

EID: 84890852266     PISSN: 15734099     EISSN: 18756697     Source Type: Journal    
DOI: 10.2174/15734099113096660039     Document Type: Review

References (149)

1. Carlsson, A. Perspectives on the discovery of central monoaminergic neurotransmission. Annu. Rev. Neurosci., 1987, 10, 19-40.
2. Clark, L.; Roiser, J.; Cools, R.; Rubinsztein, D.; Sahakian, B.; Robbins, T. Stop signal response inhibition is not modulated by tryptophan depletion or the serotonin transporter polymorphism in healthy volunteers: implications for the 5-HT theory of impulsivity. Psychopharmacology, 2005, 182, 570-578.
3. Greengard, P. The neurobiology of slow synaptic transmission. Science, 2001, 294, 1024-1030.
4. Olivier, B. Serotonin and aggression. Ann. NY. Acad. Sci., 2004, 1036, 382-392.
5. Romero-Ramos, M.; Rodriguez-Gomez, J.A.; Venero, J.L.; Cano, J.; Machado, A. Chronic inhibition of the high-affinity dopamine uptake system increases oxidative damage to proteins in the aged rat substantia nigra. Free Radical Biol. Med., 1997, 23, 1-7.
6. Volkow, N.D.; Fowler, J.S.; Wang, G.J.; Logan, J.; Schlyer, D.; MacGregor, R.; Hitzemann, R.; Wolf, A.P. Decreased dopamine transporters with age in healthy human subjects. Ann. Neurol., 1994, 36, 237-239.
7. Amara, S.G.; Kuhar, M.J. Neurotransmitter transporters: Recent progress. Ann. Rev. Neurosci., 1993, 16, 73-93.
8. Blakely, R.D.; Ramamoorthy, S.; Schroeter, S.; Qian, Y.; Apparsundaram, S.; Galli, A.; DeFelice, L.J. Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Biol. Psychiatry., 1998, 44, 169-178.
9. Murphy, D.L.; Lesch, K.-P. Targeting the murine serotonin transporter: insights into human neurobiology. Nat. Rev. Neurosci., 2008, 9, 85-96.
10. Chen, N.-H.; Reith, M.A.; Quick, M. Synaptic uptake and beyond: the sodium-and chloride-dependent neurotransmitter transporter family SLC6. Pflügers Archiv. European J. Physiol., 2004, 447, 519-531.
11. Gainetdinov, R.R.; Sotnikova, T.D.; Caron, M.G. Monoamine transporter pharmacology and mutant mice. Trends Pharmacol. Sci., 2002, 23, 367-373.
12. Kugaya, A.; Fujita, M.; Innis, R. Applications of SPECT imaging of dopaminergic neurotransmission in neuropsychiatric disorders. Ann. Nucl. Med., 2000, 14, 1-9.
13. Rabey, J.M.; Lerner, A.; Sigal, M.; Graff, E.; Oberman, Z. [3H] Dopamine uptake by platelet storage granules in schizophrenia. Life Sci., 1992, 50, 65-72.
14. Seeman, P.; Niznik, H. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J., 1990, 4, 2737-2744.
15. Reith, M.E.A.; de Costa, B.; Rice, K.C.; Jacobson, A.E. Evidence for mutually exclusive binding of cocaine, BTCP, GBR 12935, and dopamine to the dopamine transporter. European J. Pharmacol.: Mol. Pharmacol., 1992, 227, 417-425.
16. Ritz, M.; Lamb, R.; Goldberg; Kuhar, M. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science, 1987, 237, 1219-1223.
17. Sandoval, V.; Riddle, E.L.; Ugarte, Y.V.; Hanson, G.R.; Fleckenstein, A.E. Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J. Neurosci., 2001, 21, 1413-1419.
18. Saunders, C.; Ferrer, J.V.; Shi, L.; Chen, J.; Merrill, G.; Lamb, M.E.; Leeb-Lundberg, L.M.F.; Carvelli, L.; Javitch, J.A.; Galli, A. Amphetamine-induced loss of human dopamine transporter activity: An internalization-dependent and cocaine-sensitive mechanism. Proc. Natl. Acad. Sci., 2000, 97, 6850-6855.
19. Nelson, N. The family of Na+/Cl-neurotransmitter transporters. J. Neurochem., 1998, 71, 1785-1803.
20. Rasmussen, S.G.F.; Gether, U. Purification and fluorescent labeling of the human serotonin transporter. Biochemistry, 2005, 44, 3494-3505.
21. Yamashita, A.; Singh, S.K.; Kawate, T.; Jin, Y.; Gouaux, E. Crystal structure of a bacterial homologue of Na+/Cl--dependent neurotransmitter transporters. Nature, 2005, 437, 215-223.
22. Beuming, T.; Shi, L.; Javitch, J.A.; Weinstein, H. A comprehensive structure-based alignment of prokaryotic and eukaryotic neurotransmitter/Na+ symporters (NSS) aids in the use of the leut structure to probe nss structure and function. Mol. Pharmacol., 2006, 70, 1630-1642.
23. Henry, L.K.; Field, J.R.; Adkins, E.M.; Parnas, M.L.; Vaughan, R.A.; Zou, M.-F.; Newman, A.H.; Blakely, R.D. Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. J. Biol. Chem., 2006, 281, 2012-2023.
24. Singh, S.K. LeuT: A prokaryotic stepping stone on the way to a eukaryotic neurotransmitter transporter structure. Channels, 2008, 2, 380-389.
25. Jørgensen, A.M.; Tagmose, L.; Jørgensen, A.M.M.; Bøgesø, K.P.; Peters, G.H. Molecular dynamics simulations of Na+/Cl--dependent neurotransmitter transporters in a membrane-aqueous system. ChemMedChem, 2007, 2, 827-840.
26. Andersen, J.; Kristensen, A.S.; Bang-Andersen, B.; Stromgaard, K. Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. Chem. Commun., 2009, 25, 3677-3692.
27. Gillman, P.K. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Brit. J. Pharmacol., 2007, 151, 737-748.
28. Waitekus, A.B.; Kirkpatrick, P. Duloxetine hydrochloride. Nat. Rev. Drug Discov., 2004, 3, 907-908.
29. Wong, D.T.; Threlkeld, P.G.; Best, K.L.; Bymaster, F.P. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J. Pharmacol. Exp. Ther., 1982, 222, 61-65.
30. Tran, P.V.; Bymaster, F.P.; McNamara, R.K.; Potter, W.Z. Dual monoamine modulation for improved treatment of major depressive disorder. J. Clin. Psychopharmacol., 2003, 23, 78-86.
31. Astrup, A.; Madsbad, S.; Breum, L.; Jensen, T.J.; Kroustrup, J.P.; Larsen, T.M. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet, 2008, 372, 1906-1913.
32. Kristensen, A.S.; Andersen, J.; Jorgensen, T.N.; Sorensen, L.; Eriksen, J.; Loland, C.J.; Stromgaard, K.; Gether, U. SLC6 Neurotransmitter transporters: structure, function, and regulation. Pharmacol. Rev., 2011, 63, 585-640.
33. Newman, A.H.; Kulkarni, S. Probes for the dopamine transporter: New leads toward a cocaine-abuse therapeutic-A focus on analogues of benztropine and rimcazole. Med. Res. Rev., 2002, 22, 429-464.
34. Jorenby, D. Clinical Efficacy of bupropion in the management of smoking cessation. Drugs, 2002, 62, 25-35.
35. von Itzstein, M.; Wu, W.-Y.; Kok, G.B.; Pegg, M.S.; Dyason, J.C.; Jin, B.; Phan, T.V.; Smythe, M.L.; White, H.F.; Oliver, S.W.; Colman, P.M.; Varghese, J.N.; Ryan, D.M.; Woods, J.M.; Bethell, R.C.; Hotham, V.J.; Cameron, J.M.; Penn, C.R. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature, 1993, 363, 418-423.
36. Jorgensen, W.L. The many roles of computation in drug discovery. Science, 2004, 303, 1813-1818.
37. Liverton, N.J.; Holloway, M.K.; McCauley, J.A.; Rudd, M.T.; Butcher, J.W.; Carroll, S.S.; DiMuzio, J.; Fandozzi, C.; Gilbert, K.F.; Mao, S.-S.; McIntyre, C.J.; Nguyen, K.T.; Romano, J.J.; Stahlhut, M.; Wan, B.-L.; Olsen, D.B.; Vacca, J.P. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A Protease. J. Am. Chem. Soc., 2008, 130, 4607-4609.
38. Stauffer, S.R.; Stanton, M.G.; Gregro, A.R.; Steinbeiser, M.A.; Shaffer, J.R.; Nantermet, P.G.; Barrow, J.C.; Rittle, K.E.; Collusi, D.; Espeseth, A.S.; Lai, M.-T.; Pietrak, B.L.; Holloway, M.K.; McGaughey, G.B.; Munshi, S.K.; Hochman, J.H.; Simon, A.J.; Selnick, H.G.; Graham, S.L.; Vacca, J.P. Discovery and SAR of isonicotinamide BACE-1 inhibitors that bind beta-secretase in a Nterminal 10s-loop down conformation. Bioorg. Med. Chem. Lett., 2007, 17, 1788-1792.
39. Mackerell, A.D. Empirical force fields for biological macromolecules: Overview and issues. J. Comput Chem., 2004, 25, 1584-1604.
40. Guvench, O.; MacKerell, A.D. Kukol, A., Ed.; Humana Press, 2008; Vol. 443, pp 63-88.
41. Zhou, Z.; Zhen, J.; Karpowich, N.K.; Law, C.J.; Reith, M.E.A.; Wang, D.-N. Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat. Struct. Mol. Biol., 2009, 16, 652-657.
42. Guvench, O.; MacKerell Jr, A.D. Computational evaluation of protein-small molecule binding. Curr. Opin. Struc. Biol., 2009, 19, 56-61.
43. Tuckerman, M.E.; Martyna, G.J. Understanding modern molecular dynamics: techniques and applications. J. Phys. Chem. B, 1999, 104, 159-178.
44. Simonson, T. Free energy calculations. Marcel Dekker, Inc, 2001.
45. Tembre, B.L.; McCammon, J.A. Ligand-receptor interactions. Comput. Chem., 1984, 8, 281-283.
46. Warshel, A.; Sussman, F.; King, G. Free energy of charges in solvated proteins: microscopic calculations using a reversible charging process. Biochemistry, 1986, 25, 8368-8372.
47. Shirts, M.R.; Mobley, D.L.; Chodera, J.D. In Annual Reports in Computational Chemistry. Spellmeyer, D.C.; Wheeler, R., Eds.; Elsevier, 2007; Vol. 3, pp 41-59.
48. Bash, P.; Singh, U.; Brown, F.; Langridge, R.; Kollman, P. Calculation of the relative change in binding free energy of a protein-inhibitor complex. Science, 1987, 235, 574-576.
49. Lu, N.; Kofke, D.A.; Woolf, T.B. Improving the efficiency and reliability of free energy perturbation calculations using overlap sampling methods. J. Comput. Chem., 2004, 25, 28-40.
50. Beutler, T.C.; Mark, A.E.; van Schaik, R.C.; Gerber, P.R.; van Gunsteren, W.F. Avoiding singularities and numerical instabilities in free energy calculations based on molecular simulations. Chem. Phys. Lett., 1994, 222, 529-539.
51. Mobley, D.L.; Graves, A.P.; Chodera, J.D.; McReynolds, A.C.; Shoichet, B.K.; Dill, K.A. Predicting absolute ligand binding free energies to a simple model site. J. Mol. Biol, 2007, 371, 1118-1134.
52. Pearlman, D.A.; Charifson, P.S. Are free energy calculations useful in practice? A comparison with rapid scoring functions for the p38 MAP kinase protein system. J. Med. Chem., 2001, 44, 3417-3423.
53. Pearlman, D.A. Evaluating the molecular mechanics poissoníboltzmann surface area free energy method using a congeneric series of ligands to p38 MAP Kinase. J. Med. Chem., 2005, 48, 7796-7807.
54. Steinbrecher, T.; Case, D.A.; Labahn, A. A multistep approach to structure-based drug design: studying ligand binding at the human neutrophil elastase. J. Med. Chem., 2006, 49, 1837-1844.
55. Jorgensen, W.L. Efficient drug lead discovery and optimization. Acc. Chem. Res., 2009, 42, 724-733.
56. Kirkwood, J.G. Statistical mechanics of fluid mixtures. J. Chem. Phys., 1935, 3, 300-313.
57. Chipot, C.; Schulten, K. In Biophysical Analysis of Membrane Proteins; Wiley-VCH Verlag GmbH & Co. KGaA, 2008, pp 187-211.
58. Zwanzig, R.W. High-temperature equation of state by a perturbation method. I. nonpolar gases. J. Chem. Phys., 1954, 22, 1420-1426.
59. Jorgensen, W.L.; Buckner, J.K.; Boudon, S.; Tirado-Rives, J. Efficient computation of absolute free energies of binding by computer simulations. Application to the methane dimer in water. J. Chem. Phys., 1988, 89, 3742-3746.
60. Gilson, M.K.; Given, J.A.; Bush, B.L.; McCammon, J.A. The statistical-thermodynamic basis for computation of binding affinities: a critical review. Biophys. J., 1997, 72, 1047-1069.
61. Boresch, S.; Tettinger, F.; Leitgeb, M.; Karplus, M. Absolute binding free energies: a quantitative approach for their calculation. J. Phys. Chem. B, 2003, 107, 9535-9551.
62. Donnini, S.; Juffer, A.H. Calculation of affinities of peptides for proteins. J. Comput. Chem., 2004, 25(3), 393-411.
63. Roux, B.; Nina, M.; Pomes, R.; Smith, J.C. Thermodynamic stability of water molecules in the bacteriorhodopsin proton channel: a molecular dynamics free energy perturbation study. Biophy. J., 1996, 71, 670-681.
64. Lu, Y.; Yang, C.-Y.; Wang, S. Binding free energy contributions of interfacial waters in HIV-1 Protease/Inhibitor complexes. J. Am. Chem. Soc., 2006, 128, 11830-11839.
65. Qvist, J.; Davidovic, M.; Hamelberg, D.; Halle, B. A dry ligandbinding cavity in a solvated protein. Proc. Natl. Acad. Sci., 2008, 105, 6296-6301.
66. Deng, Y.; Roux, B. Calculation of standard binding free energies: aromatic molecules in the T4 lysozyme L99A mutant. J. Chem Theory Comput, 2006, 2, 1255-1273.
67. Wang, J.; Deng, Y.; Roux, B. Absolute binding free energy calculations using molecular dynamics simulations with restraining potentials. Biophys J., 2006, 91, 2798-2814.
68. Jiao, D.; Golubkov, P.A.; Darden, T.A.; Ren, P. Calculation of protein-ligand binding free energy by using a polarizable potential. Proc. Natl. Acad. Sci., 2008, 105, 6290-6295.
69. Woo, H.-J.; Roux, B. Calculation of absolute protein-ligand binding free energy from computer simulations. Proc. Natl. Acad. Sci. USA, 2005, 102, 6825-6830.
70. Lee, M.S.; Olson, M.A. Calculation of absolute protein-ligand binding affinity using path and endpoint approaches. Biophys. J., 2006, 90, 864-877.
71. Fukunishi, Y.; Mitomo, D.; Nakamura, H. Protein-Ligand binding free energy calculation by the smooth reaction path generation (srpg) method. J. Chem. Inf Model, 2009, 49, 1944-1951.
72. Doudou, S.; Burton, N.A.; Henchman, R.H. Standard free energy of binding from a one-dimensional potential of mean force. J. Chem. Theory Comput., 2009, 5, 909-918.
73. Gan, W.; Roux, B. Binding specificity of SH2 domains: Insight from free energy simulations. Proteins: Struct. Funct. Bioinf., 2009, 74, 996-1007.
74. Ge, X.; Roux, B. Calculation of the standard binding free energy of sparsomycin to the ribosomal peptidyl-transferase P-site using molecular dynamics simulations with restraining potentials. J. Mol. Recognit., 2010, 23, 128-141.
75. Lee, M.S.; Olson, M.A. Calculation of absolute ligand binding free energy to a ribosome-targeting protein as a function of solvent model. J. Phys. Chem. B, 2008, 112, 13411-13417.
76. Rodinger, T.; Pomes, R. Enhancing the accuracy, the efficiency and the scope of free energy simulations. Curr. Opin. Struct. Biol., 2005, 15, 164-170.
77. Rick, S.W.; Stuart, S.J. In Reviews in Computational Chemistry; John Wiley & Sons, Inc., 2003, pp 89-146.
78. Alonso, H.; Bliznyuk, A.A.; Gready, J.E. Combining docking and molecular dynamic simulations in drug design. Med. Res. Rev., 2006, 26, 531-568.
79. Zhong SJ, M.A., MacKerell AD. Computational identification of inhibitors of protein-protein interactions. Curr. Top. Med. Chem., 2007, 7, 63-82.
80. Brooijmans, N.; Kuntz, I.D. Molecular recognition and docking algorithms. Ann. Rev. Biophys. Biomol. Struct., 2003, 32, 335-373.
81. Sousa, S.F.; Fernandes, P.A.; Ramos, M.J. Protein-ligand docking: Current status and future challenges. Proteins: Struct. Funct. Bioinf., 2006, 65, 15-26.
82. Rajamani R, G.A. Ranking poses in structure-based lead discovery and optimization: current trends in scoring function development. Curr. Opin. Drug Discov. Dev., 2007, 10, 308-315.
83. Clark, R.D.; Strizhev, A.; Leonard, J.M.; Blake, J.F.; Matthew, J.B. Consensus scoring for ligand/protein interactions. J. Mol. Graph. Model., 2002, 20, 281-295.
84. Feher, M. Consensus scoring for protein-ligand interactions. Drug. Discov. Today, 2006, 11, 421-428.
85. Oda, A.; Tsuchida, K.; Takakura, T.; Yamaotsu, N.; Hirono, S. Comparison of consensus scoring strategies for evaluating computational models of protein-ligand complexes. J. Chem. Inf. Model., 2005, 46, 380-391.
86. Konstantinou-Kirtay, C.; Mitchell, J.; Lumley, J. Scoring functions and enrichment: a case study on Hsp90. BMC Bioinformatics, 2007, 8, 27.
87. Chang, C.-E.A.; Chen, W.; Gilson, M.K. Ligand configurational entropy and protein binding. Proc. Natl. Acad. Sci., 2007, 104, 1534-1539.
88. Ruvinsky, A.M. Role of binding entropy in the refinement of protein-ligand docking predictions: Analysis based on the use of 11 scoring functions. J. Comput. Chem., 2007, 28, 1364-1372.
89. Pan, Y.; Huang, N.; Cho, S.; MacKerell, A.D. Consideration of molecular weight during compound selection in virtual target-based database screening. J. Chem. Inf. Comput. Sci., 2002, 43, 267-272.
90. Jacobsson, M.; Karlen, A. Ligand bias of scoring functions in structure-based virtual screening. J. Chem. Inf. Model., 2006, 46, 1334-1343.
91. Carta, G.; Knox, A.J.S.; Lloyd, D.G. Unbiasing scoring functions: A new normalization and rescoring strategy. J. Chem. Inf. Model., 2007, 47, 1564-1571.
92. Honig, B.; Nicholls, A. Classical electrostatics in biology and chemistry. Science, 1995, 268, 1144-1149.
93. Still, C.; Tempczyk, A.; Hawley, R.; Hendrickson, T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J. Am. Chem. Soc., 1990, 112, 6127-6129.
94. Dodson, G.G.; Lane, D.P.; Verma, C.S. Molecular simulations of protein dynamics: new windows on mechanisms in biology. EMBO Rep., 2008, 9, 144-150.
95. Wong, C.F. Flexible ligand-flexible protein docking in protein kinase systems. Biochim. Biophys. Acta., 2008, 1784, 244-251.
96. Totrov, M.; Abagyan, R. Flexible ligand docking to multiple receptor conformations: a practical alternative. Curr. Opin. Struct. Biol., 2008, 18, 178-184.
97. Amaro, R.; Baron, R.; McCammon, J. An improved relaxed complex scheme for receptor flexibility in computer-aided drug design. J. Comput.-Aided Mol. Des., 2008, 22, 693-705.
98. Nabuurs, S.B.; Wagener, M.; de Vlieg, J. A flexible approach to induced fit docking. J. Med. Chem., 2007, 50, 6507-6518.
99. Li, Z.; Lazaridis, T. Water at biomolecular binding interfaces. Phys. Chem. Chem. Phys., 2007, 9, 573-581.
100. Young, T.; Abel, R.; Kim, B.; Berne, B.J.; Friesner, R.A. Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding. Proc. Natl. Acad. Sci., 2007, 104, 808-813.
101. Rarey, M.; Kramer, B.; Lengauer, T. The particle concept: placing discrete water molecules during protein-ligand docking predictions. Proteins: Struct. Funct. Bioinf., 1999, 34, 17-28.
102. Mancera, R. Molecular modeling of hydration in drug design. Curr. Opin. Drug Discov. Devel., 2007, 10, 275-280.
103. de Azevedo WFJ, D.R. Computational methods for calculation of ligand-binding affinity. Curr. Drug Targets, 2008, 9, 1031-1039.
104. KontoyianniM, M.P., Suchanek E, SeibelW. Theoretical and practical considerations in virtual screening: a beaten field? Curr. Med. Chem., 2008, 15, 107-116.
105. Moitessier, N.; Englebienne, P.; Lee, D.; Lawandi, J.; Corbeil, C.R. Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go. Brit J. Pharmacol., 2008, 153, S7-S26.
106. Singh, N.; Warshel, A. Absolute binding free energy calculations: On the accuracy of computational scoring of protein-ligand interactions. Proteins: Struct. Funct. Bioinf., 2010, 78, 1705-1723.
107. Hou, T.; Wang, J.; Li, Y.; Wang, W. Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J. Chem. Inf. Model., 2010, 51, 69-82.
108. Guimaraes, C.R.W.; Mathiowetz, A.M. Addressing limitations with the MM-GB/SA scoring procedure using the WaterMap method and free energy perturbation calculations. J. Chem. Inf. Model., 2010, 50, 547-559.
109. de Ruiter, A.; Oostenbrink, C. Free energy calculations of proteinligand interactions. Curr. Opin. Chem. Biol., 2011, 15, 547-552.
110. Foloppe, N.; Hubbard, R. Towards predictive ligand design with free-energy based computational methods? Curr. Med. Chem., 2006, 13, 3583-3608.
111. Kollman, P.A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W.; Donini, O.; Cieplak, P.; Srinivasan, J.; Case, D.A.; Cheatham, T.E. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc. Chem. Res., 2000, 33, 889-897.
112. Wang, J.; Morin, P.; Wang, W.; Kollman, P.A. Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. J. Am. Chem. Soc., 2001, 123, 5221-5230.
113. Singh, N.; Warshel, A. A comprehensive examination of the contributions to the binding entropy of protein-ligand complexes. Proteins: Struct. Funct. Bioinf., 2010, 78, 1724-1735.
114. Gilson, M.K.; Zhou, H.-X. Calculation of protein-ligand binding affinities. Ann. Rev. Biophys. Biomol. Struct., 2007, 36, 21-42.
115. Suenaga, A.; Okimoto, N.; Hirano, Y.; Fukui, K. An efficient computational method for calculating ligand binding affinities. PLoS ONE, 2012, 7, e42846.
116. Aqvist, J.; Medina, C.; Samuelsson, J.-E. A new method for predicting binding affinity in computer-aided drug design. Prot. Eng., 1994, 7, 385-391.
117. Stjernschantz, E.; Oostenbrink, C. Improved ligand-protein binding affinity predictions using multiple binding modes. Biophys. J., 2010, 98, 2682-2691.
118. Huang, D.; Caflisch, A. Efficient Evaluation of binding free energy using continuum electrostatics solvation. J. Med. Chem., 2004, 47, 5791-5797.
119. Valiente, P.A.; Gil L, A.; Batista, P.R.; Caffarena, E.R.; Pons, T.; Pascutti, P.G. New parameterization approaches of the LIE method to improve free energy calculations of PlmII-Inhibitors complexes. J. Comput. Chem., 2010, 31, 2723-2734.
120. Huang, N.; Jacobson, M.P. Physics-based methods for studying protein-ligand interactions. Curr. Opin. Drug Discov. Devel., 2007, 10, 325-331.
121. Jiang, W.; Hodoscek, M.; Roux, B. Computation of absolute hydration and binding free energy with free energy perturbation distributed replica-exchange molecular dynamics. J. Chem. Theory Comput., 2009, 5, 2583-2588.
122. Steiner, D.; Oostenbrink, C.; Diederich, F.; Zürcher, M.; van Gunsteren, W.F. Calculation of binding free energies of inhibitors to plasmepsin II. J. Comput. Chem., 2011, 32, 1801-1812.
123. Woods, C.J.; Essex, J.W.; King, M.A. The development of replicaexchange-based free-energy methods. J. Phys. Chem. B, 2003, 107, 13703-13710.
124. Oostenbrink, C. Efficient free energy calculations on small molecule host-guest systems-A combined linear interaction energy/one-step perturbation approach. J. Comput. Chem., 2009, 30, 212-221.
125. Michel, J.; Essex, J. Prediction of protein-ligand binding affinity by free energy simulations: assumptions, pitfalls and expectations. J. Comput.-Aided Mol. Des., 2010, 24, 639-658.
126. Truhlar, D.; Chipot, C.; Pohorille, A. Eds. Free energy calculations: theory and applications in chemistry and biology. Theor. Chem. Accounts, 2008, 121, 105-106.
127. Christ, C.D.; Mark, A.E.; van Gunsteren, W.F. Basic ingredients of free energy calculations: A review. J. Comput. Chem., 2010, 31, 1569-1582.
128. Huang, X.; Zhan, C.-G. How dopamine transporter interacts with dopamine: insights from molecular modeling and simulation. Biophys. J., 2007, 93, 3627-3639.
129. Dar, D.E.; Metzger, T.G.; Vandenbergh, D.J.; Uhl, G.R. Dopamine uptake and cocaine binding mechanisms: The involvement of charged amino acids from the transmembrane domains of the human dopamine transporter. Eur. J. Pharmacol., 2006, 538, 43-47.
130. Lin, Z.; Zhang, P.-W.; Zhu, X.; Melgari, J.-M.; Huff, R.; Spieldoch, R.L.; Uhl, G.R. Phosphatidylinositol 3-Kinase, protein kinase C, and MEK1/2 kinase regulation of dopamine transporters (DAT) require N-terminal DAT phosphoacceptor sites. J. Biol. Chem., 2003, 278, 20162-20170.
131. Guptaroy, B.; Zhang, M.; Bowton, E.; Binda, F.; Shi, L.; Weinstein, H.; Galli, A.; Javitch, J.A.; Neubig, R.R.; Gnegy, M.E. A juxtamembrane mutation in the N terminus of the dopamine transporter induces preference for an inward-facing conformation. Mol. Pharmacol., 2009, 75, 514-524.
132. Phillips, J.C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R.D.; Kalé, L.; Schulten, K. Scalable molecular dynamics with NAMD. J. Comput. Chem., 2005, 26, 1781-1802.
133. Henin, J.; Maigret, B.; Tarek, M.; Escrieut, C.; Fourmy, D.; Chipot, C. Probing a model of a GPCR/ligand complex in an explicit membrane environment: the human Cholecystokinin-1 receptor. Biophys. J., 2006, 90, 1232-1240.
134. Brooks, B.R.; Brooks, C.L.; Mackerell, A.D.; Nilsson, L.; Petrella, R.J.; Roux, B.; Won, Y.; Archontis, G.; Bartels, C.; Boresch, S.; Caflisch, A.; Caves, L.; Cui, Q.; Dinner, A.R.; Feig, M.; Fischer, S.; Gao, J.; Hodoscek, M.; Im, W.; Kuczera, K.; Lazaridis, T.; Ma, J.; Ovchinnikov, V.; Paci, E.; Pastor, R.W.; Post, C.B.; Pu, J.Z.; Schaefer, M.; Tidor, B.; Venable, R.M.; Woodcock, H.L.; Wu, X.; Yang, W.; York, D.M.; Karplus, M. CHARMM: The biomolecular simulation program. J. Comput. Chem., 2009, 30, 1545-1614.
135. Huang, X.; Gu, H.H.; Zhan, C.-G. Mechanism for cocaine blocking the transport of dopamine: insights from molecular modeling and dynamics simulations. J. Phys. Chem. B, 2009, 113, 15057-15066.
136. Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K.; Olson, A.J. Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem., 1998, 19, 1639-1662.
137. Case, D.A.; Darden, T.A.; Cheatham, T.E. III.; Simmerling, C.L.; Wang, J.; Duke, R.E.; Luo, R.; Merz, K.M.; Wang, B.; Pearlman, D.A.; Crowley, M.; Brozell, S.; Tsui, V.; Gohlke, H.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; Schafmeister, C.; Caldwell, Ross, W.S.; Kollman P.A. AMBER 8, 2004 University of California, San Francisco.
138. Gao, D.; Zhan, C.-G. Modeling effects of oxyanion hole on the ester hydrolysis catalyzed by human cholinesterases. J. Phys. Chem. B, 2005, 109, 23070-23076.
139. Pan, Y.; Gao, D.; Yang, W.; Cho, H.; Yang, G.; Tai, H.-H.; Zhan, C.-G. Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc. Natl. Acad. Sci. USA, 2005, 102, 16656-16661.
140. Zhan, C.-G.; Gao, D. Catalytic mechanism and energy barriers for butyrylcholinesterase-catalyzed hydrolysis of cocaine. Biophys. J., 2005, 89, 3863-3872.
141. Hill, E.R.; Huang, X.; Zhan, C.-G.; Ivy Carroll, F.; Gu, H.H. Interaction of tyrosine 151 in norepinephrine transporter with the 2β group of cocaine analog RTI-113. Neuropharmacology, 2011, 61, 112-120.
142. Case, D.A.; Darden, T.A.; Cheatham, T.E. III.; Simmerling, C.L.; Wang, J.; Duke, R.E.; Luo, R.; Merz, K.M.; Pearlman, D.A.; Crowley, M.; Walker, R.C.; Zhang, W.; Wang, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Wong, K.F.; Paesani, F.; Wu, X.; Brozell, S.; Tsui, V.; Gohlke, H.; Yang, L.; Tan, C.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; Mathews, D.H.; Schafmeister, C.; Ross, W.S.; Kollman P.A. AMBER 9, 2006 University of California, San Francisco.
143. Henry, L.K.; Iwamoto, H.; Field, J.R.; Kaufmann, K.; Dawson, E.S.; Jacobs, M.T.; Adams, C.; Felts, B.; Zdravkovic, I.; Armstrong, V.; Combs, S.; Solis, E.; Rudnick, G.; Noskov, S.Y.; DeFelice, L.J.; Meiler, J.; Blakely, R.D. A conserved asparagine residue in transmembrane segment 1 (TM1) of serotonin transporter dictates chloride-coupled neurotransmitter transport. J. Biol Chem., 2011, 286, 30823-30836.
144. Simonson, T.; Carlsson, J.; Case, D.A. Proton binding to proteins: pka calculations with explicit and implicit solvent models. J. Am. Chem. Soc., 2004, 126, 4167-4180.
145. Kaufmann, K.W.; Dawson, E.S.; Henry, L.K.; Field, J.R.; Blakely, R.D.; Meiler, J. Structural determinants of species-selective substrate recognition in human and Drosophila serotonin transporters revealed through computational docking studies. Proteins: Struct. Funct. Bioinf., 2009, 74, 630-642.
146. Foloppe, N.; Nilsson, L. Stabilization of the catalytic thiolate in a mammalian glutaredoxin: structure, dynamics and electrostatics of reduced pig glutaredoxin and its mutants. J. Mol. Biol., 2007, 372, 798-816.
147. Anisimov, V.M.; Lamoureux, G.; Vorobyov, I.V.; Huang, N.; Roux, B.; MacKerell, A.D. Determination of electrostatic parameters for a polarizable force field based on the classical drude oscillator. J. Chem. Theory Comput., 2004, 1, 153-168.
148. Vanommeslaeghe, K.; Hatcher, E.; Acharya, C.; Kundu, S.; Zhong, S.; Shim, J.; Darian, E.; Guvench, O.; Lopes, P.; Vorobyov, I.; Mackerell, A.D. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J. Comput. Chem., 2010, 31, 671-690.
149. Singh, S.K.; Piscitelli, C.L.; Yamashita, A.; Gouaux, E. A Competitive Inhibitor Traps LeuT in an Open-to-Out Conformation. Science, 2008, 322(5908), 1655-1661.